Company intelligence / Profile preview

Leads Biolabs

Nanjing, China

Ownership: Public · 09887
Development stage: Phase 1

Overview

Multiple programs in clinical development including LBL-007 (LAG-3 antibody) with Phase Ib/II results published in Journal of Hematology & Oncology, LBL-034 (GPRC5D/CD3 bispecific antibody) received Orphan Drug Designation from FDA for multiple myeloma, and LBL-024 (PD-L1/4-1BB bispecific antibody) in development for neuroendocrine cancer

Therapeutic areas: OncologyImmunologyMetabolic Disorders
Modalities: Monoclonal antibodiesbispecific antibodiesT cell engagersantibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

18 assets

opamtistomig

17 more assets in the full pipeline.

Request access →

Partnerships

Aditum Bio (formed Oblenio Bio to develop LBL-051)

Beyond the preview

Go deeper on Leads Biolabs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leads Biolabs.

Explore the full profile